Omalizumab in severe asthma and food allergies with IgE levels >1500 kU/L: Two-year evaluation
- PMID: 38146110
- DOI: 10.1111/pai.14057
Omalizumab in severe asthma and food allergies with IgE levels >1500 kU/L: Two-year evaluation
References
REFERENCES
-
- Menzella F, Just J, Sauerbeck IS, et al. Omalizumab for the treatment of patients with severe allergic asthma with immunoglobulin E levels above >1500 IU/mL. World Allergy Organ J. 2023;16(6):100787. doi:10.1016/j.waojou.2023.100787
-
- Johansson SGO, Haahtela T, O'Byrne PM. Omalizumab and the immune system: an overview of preclinical and clinical data. Ann Allergy Asthma Immunol. 2002;89(2):132-138. doi:10.1016/S1081-1206(10)61928-X
-
- Molderings GJ, Dumoulin FL, Homann J, et al. Adrenal insufficiency is a contraindication for omalizumab therapy in mast cell activation disease: risk for serum sickness. Naunyn Schmiedebergs Arch Pharmacol. 2020;393(9):1573-1580. doi:10.1007/S00210-020-01886-2
-
- Dahdah L, Ceccarelli S, Amendola S, et al. IgE Immunoadsorption knocks down the risk of food-related anaphylaxis. Pediatrics. 2015;136(6):e1617-e1620. doi:10.1542/PEDS.2015-1757
-
- Arasi S, Piscitelli AL, Cafarotti A, et al. IgE-immunoadsorption for severe allergy to multiple foods: a case series of five children. World Allergy Organ J. 2023;16(2):100750. doi:10.1016/J.WAOJOU.2023.100750
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
